Hypertension
Adult: Initially, 10 mg once daily, may increase to 20 mg once daily after at least 2 weeks according to patient's response.
Chỉ định và Liều dùng
Oral
Hypertension Adult: Initially, 10 mg once daily, may increase to 20 mg once daily after at least 2 weeks according to patient's response.
|
||||
Các thuốc khác
|
||||
Suy thận
|
||||
Suy gan
Severe: Contraindicated.
|
||||
Cách dùng
Lercanidipine Should be taken on an empty stomach.
|
||||
Chống chỉ định
Left ventricular outflow obstruction (aortic stenosis), untreated CHF, unstable angina, recent MI (within 1 month). Severe hepatic and renal impairment (CrCl <30 mL/min). Pregnancy and lactation. Concomitant use with strong CYP3A4 inhibitors, and cyclosporin.
|
||||
Thận trọng
Patient with sick sinus syndrome without a functioning pacemaker, left ventricular dysfunction, ischaemic heart disease. Mild to moderate renal and hepatic impairment.
|
||||
Tác dụng không mong muốn
Significant: Angina pectoris, hypotension.
Cardiac disorders: Tachycardia, palpitations. Gastrointestinal disorders: Dyspepsia, nausea, upper abdominal pain. General disorders and admin site conditions: Peripheral oedema, asthenia, fatigue. Musculoskeletal and connective tissue disorders: Myalgia. Nervous system disorders: Headache, dizziness. Renal and urinary disorders: Polyuria. Skin and subcutaneous tissue disorders: Rash, pruritus. Vascular disorders: Flushing. |
||||
PO: Z (Embryo-foetal lethality and abnormalities were observed in animal studies. Not recommended.)
|
||||
Thông tin tư vấn bệnh nhân
This drug may cause dizziness, weakness and fatigue, if affected, do not drive or operate machinery.
|
||||
Chỉ số theo dõi
Monitor heart rate and blood pressure.
|
||||
Quá liều
Symptoms: Peripheral vasodilation, hypotension, tachycardia, bradycardia and negative inotropic effect (at very high doses), dizziness, headache and palpitations. Management: Supportive treatment. Monitor cardiac and respiratory function, circulating fluid volume, and urine output.
|
||||
Tương tác
Reduced antihypertensive effect with CYP3A4 inducers (e.g. phenytoin, rifampicin). Increased absorption with midazolam. Decreased serum concentration with metoprolol.
Potentially Fatal: Increased serum concentration with ciclosporin and strong CYP3A4 inhibitors (e.g. ketoconazole, ritonavir, erythromycin). |
||||
Tương tác với thức ăn
Enhanced vasodilatory effect with alcohol. Increased serum concentration with grapefruit juice.
|
||||
Tác dụng
Description:
Mechanism of Action: Lercanidipine is a dihydropyridine calcium antagonist which selectively inhibits the transmembrane influx of Ca into cardiac and vascular smooth muscle (greater effect on vascular than on cardiac smooth muscle) during depolarisation. It reduces peripheral vascular resistance which leads to lower arterial blood pressure by directly relaxing the vascular smooth muscle. Duration: 24 hours. Pharmacokinetics: Absorption: Rapidly and completely absorbed from the gastrointestinal tract. Bioavailability: Approx 10%. Time to peak plasma concentration: Approx 1.5-3 hours. Distribution: Rapidly and widely distributed to tissues and organs. Volume of distribution: 2 to 2.5 L/kg. Plasma protein binding: >98%. Metabolism: Extensively metabolised by CYP3A4 into inactive metabolites; undergoes extensive first-pass metabolism. Excretion: Via urine (approx 50% as metabolites). Elimination half-life: 8-10 hours. |
||||
Đặc tính
![]() Source: National Center for Biotechnology Information. PubChem Database. Lercanidipine, CID=65866, https://pubchem.ncbi.nlm.nih.gov/compound/Lercanidipine (accessed on Jan. 22, 2020) |
||||
Bảo quản
Store below 30°C. Protect from light and moisture.
|
||||
Phân loại MIMS
|
||||
Phân loại ATC
C08CA13 - lercanidipine ; Belongs to the class of dihydropyridine derivative selective calcium-channel blockers with mainly vascular effects. Used in the treatment of cardiovascular diseases.
|
||||
Tài liệu tham khảo
Anon. Lercanidipine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. https://online.lexi.com. Accessed 18/05/2021. Buckingham R (ed). Lercanidipine Hydrochloride. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. https://www.medicinescomplete.com. Accessed 18/05/2021. Zanidip 20 mg Tablets (Recordati Industria Chimica e Farmaceutica S.p.A). MHRA. https://products.mhra.gov.uk. Accessed 18/05/2021. Zanidip Film-Coated Tablets (Recordati Industria Chimica e Farmaceutica S.p.A). National Pharmaceutical Regulatory Agency - Ministry of Health Malaysia. https://www.npra.gov.my. Accessed 18/05/2021.
|